Law360, New York (September 09, 2010, 3:11 PM ET) -- A federal judge has nixed some state claims and allowed others to stand in an indirect purchaser action accusing GlaxoSmithKline PLC of filing baseless patent suits to delay generic competition over Wellbutrin SR, issuing his opinion after considering each individual claim in the context of applicable state law.
Ruling in the U.S. District Court for the Eastern District of Pennsylvania on Wednesday, Judge Lawrence Stengel allowed at least one claim of every named plaintiff in the suit, brought by employee benefit plans, to proceed.
The indirect...
Indirect Buyers' Wellbutrin Antitrust Suit Lives On
To view the full article, take a free trial now.
